BACKGROUND: Diabetes may be an independent risk factor for atrial fibrillation. However, results from prior studies are in conflict, and no study has examined diabetes duration or glycemic control. OBJECTIVE: To examine the association of diabetes with risk of atrial fibrillation and to describe risk according to diabetes duration and glycemic control. DESIGN: A population-based case-control study. PARTICIPANTS: Within a large, integrated healthcare delivery system, we identified 1,410 people with newly-recognized atrial fibrillation from ICD-9 codes and validated cases by review of medical records. 2,203 controls without atrial fibrillation were selected from enrollment lists, stratified on age, sex, hypertension, and calendar year. MAIN MEASURES: Information on atrial fibrillation, diabetes and other characteristics came from medical records. Diabetes was defined based on physician diagnoses recorded in the medical record, and pharmacologically treated diabetes was defined as receiving antihyperglycemic medications. Information about hemoglobin A1c levels came from computerized laboratory data. KEY RESULTS: Among people with atrial fibrillation, 252/1410 (17.9%) had pharmacologically treated diabetes compared to 311/2203 (14.1%) of controls. The adjusted OR for atrial fibrillation was 1.40 (95% CI 1.15-1.71) for people with treated diabetes compared to those without diabetes. Among those with treated diabetes, the risk of developing atrial fibrillation was 3% higher for each additional year of diabetes duration (95% CI 1-6%). Compared to people without diabetes, the adjusted OR for people with treated diabetes with average hemoglobin A1c <or=7 was 1.06 (95% CI 0.74-1.51); for A1c >7 but <or=8, 1.48 (1.09-2.01); for A1c >8 but <or=9, 1.46 (1.02-2.08); and for A1c >9, 1.96 (1.22-3.14). CONCLUSIONS: Diabetes was associated with higher risk of developing atrial fibrillation, and risk was higher with longer duration of treated diabetes and worse glycemic control. Future research should identify and test approaches to reduce the risk of atrial fibrillation in people with diabetes.
BACKGROUND:Diabetes may be an independent risk factor for atrial fibrillation. However, results from prior studies are in conflict, and no study has examined diabetes duration or glycemic control. OBJECTIVE: To examine the association of diabetes with risk of atrial fibrillation and to describe risk according to diabetes duration and glycemic control. DESIGN: A population-based case-control study. PARTICIPANTS: Within a large, integrated healthcare delivery system, we identified 1,410 people with newly-recognized atrial fibrillation from ICD-9 codes and validated cases by review of medical records. 2,203 controls without atrial fibrillation were selected from enrollment lists, stratified on age, sex, hypertension, and calendar year. MAIN MEASURES: Information on atrial fibrillation, diabetes and other characteristics came from medical records. Diabetes was defined based on physician diagnoses recorded in the medical record, and pharmacologically treated diabetes was defined as receiving antihyperglycemic medications. Information about hemoglobin A1c levels came from computerized laboratory data. KEY RESULTS: Among people with atrial fibrillation, 252/1410 (17.9%) had pharmacologically treated diabetes compared to 311/2203 (14.1%) of controls. The adjusted OR for atrial fibrillation was 1.40 (95% CI 1.15-1.71) for people with treated diabetes compared to those without diabetes. Among those with treated diabetes, the risk of developing atrial fibrillation was 3% higher for each additional year of diabetes duration (95% CI 1-6%). Compared to people without diabetes, the adjusted OR for people with treated diabetes with average hemoglobin A1c <or=7 was 1.06 (95% CI 0.74-1.51); for A1c >7 but <or=8, 1.48 (1.09-2.01); for A1c >8 but <or=9, 1.46 (1.02-2.08); and for A1c >9, 1.96 (1.22-3.14). CONCLUSIONS:Diabetes was associated with higher risk of developing atrial fibrillation, and risk was higher with longer duration of treated diabetes and worse glycemic control. Future research should identify and test approaches to reduce the risk of atrial fibrillation in people with diabetes.
Authors: T S Tsang; M E Barnes; K R Bailey; C L Leibson; S C Montgomery; Y Takemoto; P M Diamond; M A Marra; B J Gersh; D O Wiebers; G W Petty; J B Seward Journal: Mayo Clin Proc Date: 2001-05 Impact factor: 7.616
Authors: Martin K Rutter; Helen Parise; Emelia J Benjamin; Daniel Levy; Martin G Larson; James B Meigs; Richard W Nesto; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: Nicholas L Smith; Susan R Heckbert; Rozenn N Lemaitre; Alex P Reiner; Thomas Lumley; Noel S Weiss; Eric B Larson; Frits R Rosendaal; Bruce M Psaty Journal: JAMA Date: 2004-10-06 Impact factor: 56.272
Authors: Ronnier J Aviles; David O Martin; Carolyn Apperson-Hansen; Penny L Houghtaling; Pentti Rautaharju; Richard A Kronmal; Russell P Tracy; David R Van Wagoner; Bruce M Psaty; Michael S Lauer; Mina K Chung Journal: Circulation Date: 2003-11-17 Impact factor: 29.690
Authors: Rachel R Huxley; Alvaro Alonso; Faye L Lopez; Kristian B Filion; Sunil K Agarwal; Laura R Loehr; Elsayed Z Soliman; James S Pankow; Elizabeth Selvin Journal: Heart Date: 2011-09-19 Impact factor: 5.994
Authors: Steven A Lubitz; Xiaoyan Yin; João D Fontes; Jared W Magnani; Michiel Rienstra; Manju Pai; Mark L Villalon; Ramachandran S Vasan; Michael J Pencina; Daniel Levy; Martin G Larson; Patrick T Ellinor; Emelia J Benjamin Journal: JAMA Date: 2010-11-13 Impact factor: 56.272
Authors: Omid Fatemi; Eugene Yuriditsky; Costas Tsioufis; Demetrios Tsachris; Timothy Morgan; Jan Basile; Thomas Bigger; William Cushman; David Goff; Elsayed Z Soliman; Abraham Thomas; Vasilios Papademetriou Journal: Am J Cardiol Date: 2014-07-30 Impact factor: 2.778
Authors: Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu Journal: Eur J Prev Cardiol Date: 2016-11-04 Impact factor: 7.804
Authors: Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu Journal: Europace Date: 2017-02-01 Impact factor: 5.214
Authors: Alvaro Alonso; Judy L Bahnson; Sarah A Gaussoin; Alain G Bertoni; Karen C Johnson; Cora E Lewis; Marion Vetter; Christos S Mantzoros; Robert W Jeffery; Elsayed Z Soliman Journal: Am Heart J Date: 2015-07-26 Impact factor: 4.749
Authors: Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin Journal: J Diabetes Complications Date: 2014-11-25 Impact factor: 2.852